dyne therapeutics, inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the united states. it develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its force platform that delivers disease-modifying therapies. the company was founded in 2017 and is based in waltham, massachusetts.
Company profile
Ticker
DYN
Exchange
Website
CEO
Joshua T. Brumm
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Dyne Therapeutics Securities Corporation ...
IRS number
364883909
DYN stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
5 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
8-K
Departure of Directors or Certain Officers
25 Mar 24
S-3ASR
Automatic shelf registration
5 Mar 24
8-K
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
5 Mar 24
S-8
Registration of securities for employees
5 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
424B5
Prospectus supplement for primary offering
5 Jan 24
8-K
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
5 Jan 24
Latest ownership filings
3/A
John Cox
4 Apr 24
4
Jonathan McNeill
4 Apr 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
4
John Cox
27 Mar 24
3
John Cox
27 Mar 24
4
SUSANNA GATTI HIGH
13 Mar 24
4
Jonathan McNeill
13 Mar 24
4
Wildon Farwell
12 Mar 24
4
Richard William Scalzo
12 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 132.60 mm | 132.60 mm | 132.60 mm | 132.60 mm | 132.60 mm | 132.60 mm |
Cash burn (monthly) | 12.44 mm | 1.22 mm | 20.76 mm | 17.88 mm | 16.87 mm | 15.20 mm |
Cash used (since last report) | 83.14 mm | 8.14 mm | 138.70 mm | 119.50 mm | 112.70 mm | 101.53 mm |
Cash remaining | 49.47 mm | 124.47 mm | -6.09 mm | 13.10 mm | 19.90 mm | 31.07 mm |
Runway (months of cash) | 4.0 | 102.2 | -0.3 | 0.7 | 1.2 | 2.0 |
Institutional ownership, Q3 2023
86.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 119 |
Opened positions | 12 |
Closed positions | 13 |
Increased positions | 47 |
Reduced positions | 32 |
13F shares | Current |
---|---|
Total value | 535.21 bn |
Total shares | 74.39 mm |
Total puts | 6.10 k |
Total calls | 63.93 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Atlas Venture Life Science Advisors | 9.89 mm | $88.57 bn |
Atlas Venture Fund XI | 7.33 mm | $0.00 |
MPM Asset Management | 4.95 mm | $44.36 bn |
MPM Bioventures 2018 | 4.95 mm | $0.00 |
BLK Blackrock | 3.31 mm | $29.63 bn |
Citadel Advisors | 3.04 mm | $27.25 bn |
Deep Track Capital | 2.40 mm | $21.54 bn |
Vanguard | 2.36 mm | $21.18 bn |
Vida Ventures II | 2.22 mm | $26.62 mm |
Vida Ventures Advisors | 2.22 mm | $19.89 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | John Cox | Stock Option Common Stock | Grant | Acquire A | No | No | 26.06 | 679,853 | 17.72 mm | 679,853 |
12 Mar 24 | Wildon Farwell | Common Stock | Sell | Dispose S | No | Yes | 25.58 | 1,030 | 26.35 k | 150,560 |
11 Mar 24 | Oxana Beskrovnaya | Common Stock | Sell | Dispose S | No | Yes | 25.7 | 2,081 | 53.48 k | 152,352 |
11 Mar 24 | Wildon Farwell | Common Stock | Sell | Dispose S | No | Yes | 25.7 | 1,585 | 40.73 k | 151,590 |
News
Oppenheimer Reiterates Outperform on Dyne Therapeutics, Maintains $47 Price Target
26 Mar 24
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
25 Mar 24
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
25 Mar 24
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
14 Mar 24
Chardan Capital Maintains Buy Rating for Dyne Therapeutics: Here's What You Need To Know
8 Mar 24
Press releases
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
27 Mar 24
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
27 Mar 24
Dyne Therapeutics Announces CEO Transition
25 Mar 24
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
13 Mar 24
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
5 Mar 24